Prevents pregnancy. ANDA 202741, held by Xiromed. Ethinyl Estradiol; Norethindrone Acetate.
As of Nov 16, 2026, ANDA 202741 (Norethindrone Acetate And Ethinyl Estradiol), held by Xiromed, was first approved by FDA on Feb 20, 2015, with 4 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Oral contraceptives are highly effective. Table I lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 20, 2015 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Norethindrone Acetate And Ethinyl Estradiol0.03MG;1.5MG · tablet;oral-28 | Ethinyl Estradiol; Norethindrone Acetate | Rx |
| Jan 5, 2024 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jan 5, 2024 | Supplement 8Labeling · Standard review | Approved | None posted |
| Nov 8, 2018 | Supplement 2Labeling · Standard review | Approved | None posted |
| Nov 8, 2018 | Supplement 3Labeling · Standard review | Approved | None posted |
| Feb 20, 2015 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters